Loading
CAR-T Cell Therapy Research / Virus-based Gene Therapy Research / CRISPR and Genetic Engineering · Journal article
International Journal of Biology and Life Sciences · August 27, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review synthesizing potential applications of CRISPR/Cas9 genome editing to enhance CAR-T cell therapy by addressing T-cell exhaustion, toxicity, and manufacturing challenges. The review identifies promising preclinical and emerging clinical directions but presents no new empirical evidence, clinical trial data, or quantified outcomes to validate these approaches. Readers should treat this as a conceptual framework and state-of-the-art summary rather than actionable evidence of efficacy.
Journal article.
CRISPR/Cas9 enables precise combinatorial genetic editing in CAR-T cells to disrupt inhibitory immune checkpoints and enhance antitumour activity Universal allogeneic CAR-T cells can be generated by deletion of T-cell receptor and HLA genes using CRISPR Cytokine signalling pathway modulation via CRISPR may reduce CAR-T toxicity
Challenges identified (off-target effects, genomic instability, long-term safety) remain unresolved and unquantified Cytokine signalling pathway modulation via CRISPR may reduce CAR-T toxicity
The source did not state who this applies to in practice.
This is a narrative review discussing potential applications of CRISPR/Cas9 in CAR-T engineering without presenting new empirical data, clinical trials, or quantified evidence to support the proposed approaches.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
A recent major breakthrough in cancer immunotherapy is the Chimeric antigen receptor-T cell (CAR-T cell) therapy, which has shown significant clinical efficacy in haematological malignancy treatment. Nonetheless, its application in a more general way is limited by a number of challenges, such as T-cell exhaustion, off-target associated toxicities, and the difficulty of personalised manufacturing. Recently, new opportunities have come into solving these problems with the introduction of clustered regularly interspaced short tandem repeats (CRISPR)-Cas9 genome editing, which has made it possible to perform precise and combinatorial genetic editing in CAR-T cells. The important applications of CRISPR in CAR-T cell engineering, which include the disruption of inhibitory immune checkpoints to enhance antitumour activity, the generation of universal allogeneic CAR-T cells by deletion of T-cell receptor and human leukocyte antigen (HLA) genes, and the modulation of cytokine signalling pathways to reduce toxicity are discussed in this review. Moreover, novel approaches, including targeted CAR integration and multiplex gene editing, are discussed as having the potential to enhance the therapeutic efficacy and scalability. In spite of these improvements, there are issues of off-target effect, delivery efficacy, genomic instability, and unaddressed issues of long-term safety. CAR-T cell therapies are likely to be improved further in future through advancements in genome editing technology, delivery methods, and synthetic biology. In general, CRISPR/Cas9-based engineering is a promising way of developing the next generation of precision cancer immunotherapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.